Quick Answer
Aspire Biopharma Holdings, Inc. reported Operating Income of -$19.35 million for fiscal year 2025.
Aspire Biopharma Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$19.35M | -1498.1% |
| 2024 | -$1.21M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.15M | -432.2% | -432.2% |
| September 30, 2024 | -$215.3K | — | — |
- Aspire Biopharma Holdings, Inc. showed a decrease of -1498.1% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Aspire Biopharma Holdings, Inc.’s operating income has declined by 1498.1% (from -$1.21 million to -$19.35 million).
- The most recent figure is from Aspire Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: